Canada Glaucoma Drugs Market Analysis

Canada Glaucoma Drugs Market Analysis


$ 3999

Canada Glaucoma Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The increasing prevalence of glaucoma, caused by factors such as an ageing population and rising awareness, is a driver of the glaucoma medications industry. Drug delivery system technological improvements help to increase treatment choices. Novartis AG, Pfizer Inc., Santen Pharmaceutical Co., Allergan (AbbVie Inc.), Bausch Health Companies Inc., Alcon (a part of Novartis AG), Merck & Co., Aerie Pharmaceuticals, Sun Pharmaceutical Industries Ltd., and Santen Inc. are the global players in the Glaucoma Drugs Market.

ID: IN10CAPH285 CATEGORY: Pharmaceuticals GEOGRAPHY: Canada AUTHOR: Saloni Shah

Buy Now

Canada Glaucoma Drugs Market Analysis Summary

Canada Glaucoma Drugs Market is valued at around $367.2 Mn in 2022 and is projected to reach $491.1 Mn by 2030, exhibiting a CAGR of 3.7% during the forecast period 2023-2030.

Glaucoma affects around 80 Mn people globally. The increasing prevalence of glaucoma, driven by factors such as an aging population and rising awareness, is a driver of the glaucoma medications industry. Technological improvements in drug delivery systems help to increase treatment alternatives. Government programs and public awareness campaigns encourage early detection and treatment. Novartis AG, Pfizer Inc., Santen Pharmaceutical Co., Allergan (AbbVie Inc.), Bausch Health Companies Inc., Alcon (a division of Novartis AG), Merck & Co., Aerie Pharmaceuticals, Sun Pharmaceutical Industries Ltd., and Santen Inc. are global players in the Glaucoma Drugs Market.

Market Dynamics

Market Growth Drivers

  1. Glaucoma's rising prevalence: Glaucoma, a chronic eye illness, is increasing the demand for effective medications to manage the disease
  2. Aging population: As the world's old population grows, so will the prevalence of glaucoma, driving up demand for glaucoma medications
  3. Technological improvements: Drug delivery system advancements, like as sustained-release implants and combination therapies, are improving the efficacy and convenience of glaucoma treatments
  4. Awareness campaigns: Healthcare organizations and glaucoma associations are promoting public awareness about the need for early detection and treatment, which is driving demand for glaucoma medications

Market Restraints

  1. Strict regulatory requirements: The stringent regulatory process for drug approvals, including clinical trials and safety assessments, can be time-consuming and costly, limiting the availability of novel glaucoma drugs
  2. Side effects and safety concerns: Some glaucoma medicines may have negative consequences on ocular and systemic health, which may discourage patients from using them and slow market growth
  3. Patent expirations: When the patents on branded glaucoma medications expire, generic alternatives enter the market, causing pricing pressures on both branded and patented drugs
  4. Low diagnostic rates: Glaucoma commonly goes misdiagnosed in its early stages due to the lack of visible symptoms, resulting in delayed treatment and potentially impeding the market expansion of glaucoma medications

Competitive Landscape

Key Players

  • Novartis AG
  • Pfizer Inc.
  • Santen Pharmaceutical Co.
  • Allergan (AbbVie Inc.)
  • Bausch Health Companies Inc.
  • Alcon (a part of Novartis AG)
  • Merck & Co.
  • Aerie Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd.
  • Santen Inc.

Development in the Glaucoma Drugs Market

VVN539 met primary study goals in a phase II clinical trial for the treatment of glaucoma in the United States. VVN539 is a first-in-class small molecule with two MOAs for the treatment of glaucoma. It operates directly on the trabecular meshwork, increasing aqueous humor outflow and therefore lowering intraocular pressure (IOP). VVN539 has shown excellent IOP lowering performance in a preclinical animal model, and this novel medicine is expected to compete in the worldwide glaucoma market.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Canada Glaucoma Drugs Market Segmentation

By Drug Class

  • Prostaglandin Analogues
  • Beta Blockers
  • Alpha Agonists
  • Carbonic Anhydrase Inhibitors
  • Others

By Disease Type

  • Open Angle Glaucoma
  • Angle Closure Glaucoma
  • Normal-Tension Glaucoma
  • Secondary Glaucoma

By Distribution Channel

  • Hospitals
  • Retail Pharmacies
  • Online Pharmacies
  • Ophthalmology Clinics

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 27 February 2024
Updated by: Shivam Zalke

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up